CAMBRIDGE, Mass., April 20, 2022 (GLOBE NEWSWIRE) — Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will participate in a fireside chat at the Raymond James LILRB/ILT Symposium: Deep Dive into “Myeloid Checkpoint” Therapeutics in Cancer taking place virtually on Tuesday, April 26, 2022 at 1:00 pm ET.
About Jounce Therapeutics
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce’s highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. JTX-8064 is currently being investigated alone and in combination with pimivalimab (formerly JTX-4014), Jounce’s internal PD-1 inhibitor, in one monotherapy and seven combination indication-specific expansion cohorts in the Phase 1/2 INNATE trial and is currently enrolling patients with advanced solid tumors in the Phase 2 portion of the study. Jounce’s most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. Pimivalimab is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce’s broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to GS-1811 (formerly JTX-1811), a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. For more information, please visit www.jouncetx.com.
Investor and Media Contacts:
Eric Laub
Jounce Therapeutics, Inc.
+1-857-259-3853
elaub@jouncetx.com
Toronto, Ontario--(Newsfile Corp. - February 3, 2026) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF)…
GARLAND, Texas, Feb. 3, 2026 /PRNewswire/ -- Massimo Group (NASDAQ: MAMO) ("Massimo" or the "Company"),…
Next-Generation Decision Support Software Introduces Predictive Clinical Tools for Gastroenterology, Rheumatology, Dermatology, and PulmonologyFORT MYERS,…
After making personal health accessible to millions with Fitbit, James Park and Eric Friedman announce…
COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026 Interim Report Q4 and Full…
The collaboration positions the UAE as a global leader in conservation, driving pioneering initiatives in…